Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 6, 1999, Pages 685-694

  Dyer, Kyle R ^b   Foster, David J R ^b   White, Jason M ^b   Somogyi, Andrew A ^b   Menelaou, Andrew ^b   Bochner, Felix ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; OPIATE AGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATHING RATE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEROIN DEPENDENCE; HUMAN; MALE; METHADONE TREATMENT; PAIN THRESHOLD; PRIORITY JOURNAL; PUPIL; RACEMIC MIXTURE; STEADY STATE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; PAIN THRESHOLD; PUPIL; RESPIRATION; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 0033017188     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)90090-5     Document Type: Article

References (41)

1. 1. Isbell H, Wikler A, Eisenman AJ, Dangerfield M, Frank K. Liability of addiction to 6-dimethylamino-4-4-diphenyl-3-heptanone (methadon, "Amidone" or "10820") in man. Arch Intern Med 1948;82:362-92.
2. 2. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965;193:646-50.
3. 3. Meresaar U, Nilsson MI, Holmstrand J, Anggård E. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol 1981;20:473-8.
4. 4. Wolff K, Rostami-Hodjegan A, Shires S, Hay AWM, Feely M, Calvert R, et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 1997;44:325-34.
5. 5. Farrell M, Ward J, Mattick R, Hall W, Stimson GV, des Jarlais D, et al. Methadone maintenance treatment in opiate dependence: a review. Br Med J 1994;309:997-1001.
6. 6. Dole VP, Waymond Robinson J, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969;280:1372-5.
7. 7. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979;2:485-8.
8. H. Gunne L, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981;7:149-256.
9. 9. Kreek MJ. Methadone maintenance treatment for harm reduction approach to heroin addiction. In: Loimer N, Schmid R, Springer A, editors. Drug addiction and AIDS. New York: Springer-Verlag; 1991. p. 153-77.
10. 10. Strain EC, Stitzer ML, Liebson RA, Bigelow GE. Dose-response effects of methadone in treatment of opioid dependence. Ann Intern Med 1993;119:23-7.
11. 11. Gerstein DR, Harwood HJ, editors. A study of the evolution, effectiveness, and financing of public and private drug treatment systems. Treating Drug Problems; vol 1. Washington: National Academy Press; 1990.
12. 12. McLellan AT, Woody GE, Luborsky L, Goehl L. Is the counselor an "active ingredient" in substance abuse rehabilitation? An examination of treatment success among four counselors. J Nerv Ment Dis 1988;176:423-30.
13. 13. Bell J, Chan J, Kuk A. Investigating the influence of treatment philosophy on outcome of methadone maintenance. Addiction 1995;90:823-30.
14. 14. Dole VP. Methadone treatment and the acquired immunodeficiency syndrome epidemic. JAMA 1989;262:1681-2.
15. 15. Cooper JR. Ineffective use of psychoactive drags. JAMA 1992;267:281-2.
16. 16. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. New York: Springer-Verlag; 1991.
17. 17. Caplehorn JR. Bell J, Kleinbaum DG, Gebski VJ. Methadone dose and heroin use during maintenance treatment. Addiction 1993;88:119-24.
18. 18. Holmstrand J, Anggård E, Gunne LM. Methadone maintenance: plasma levels and therapeutic outcome. Clin Pharmacol Ther 1977;23:175-80.
19. 19. Bell J, Seres V, Bowron P, Lewis J, Batey R. The use of serum methadone levels in patients receiving methadone maintenance. Clin Pharmacol Ther 1988;43:623-9.
20. 20. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA 1988;260:3025-9.
21. 21. Horns WH, Rado M, Goldstein A. Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride. Clin Pharmacol Ther 1975;17:636-49.
22. 22. Dyer, KR, White JM. Patterns of symptom complaints in methadone maintenance patients. Addiction 1997;92: 1445-55.
23. 23. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972;13:923-30.
24. 24. Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 1977;21:147-57.
25. 25. Olsen GD, Wilson JE, Robertson GE. Respiratory and ventilatory effects of methadone in healthy women. Clin Pharmacol Ther 1981;29:373-80.
26. 26. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987;41:392-401.
27. 27. Verebely K, Volavka J, Mulé S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975;18: 180-90.
28. 28. Nilsson MI, Anggård E, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. Eur J Clin Pharmacol 1982;22:343-9.
29. 29. Nilsson MI, Grönbladh L, Widerlov, E, Anggård E. Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. Eur J Clin Pharmacol 1983;25:497-501.
30. 30. Wolff K, Hay AWM, Raistrick D, Calvert R. Steady-state pharmacokinetics of methadone in opioid addicts. Eur J Clin Pharmacol 1993;44:189-94.
31. 31. de Vos JW, Geerlings PJ, van den Brink W, Ufkes JGR, van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995;48:361-6.
32. 32. Haert/en C, Hickey J. Addiction Research Center Inventory (ARCI): measurement of euphoria and other drug effects. In: Bozarth M, editor. Methods of assessing the reinforcing properties of abused drugs. New York: Springer-Verlag. 1987, p. 489-524.
33. 33. Norusis M. SPSS for Windows base system users guide. Chicago: SPSS Inc; 1993.
34. 34. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6:429-53.
35. 35. Inturrisi CE, Portenoy RK, Max MB, Colburn WA, Foley KM. Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther 1990;47:565-77.
36. 36. Hiltunen AJ, Lafolie P, Martel J, Ottosson EC, Boreus LO, Beck O, et al. Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients. Psychopharmacology 1995;118:122-6.
37. 37. McCaul ME, Bigelow GE, Stitzer ML, Liebson I. Short-term effects of oral methadone in methadone maintenance subjects. Clin Pharmacol Ther 1982;31:753-61.
38. 38. Bell J, Bowron P, Lewis J, Batey R. Serum levels of methadone in maintenance clients who persist in illicit drug use. Br J Addict 1990;85:1599-602.
39. 39. Plummet JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988;33:313-22.
40. 40. Kreek MJ, Hachey DL, Klein PD. Stereoselective disposition of methadone in man. Life Sci 1979;24:925-32.
41. 41. Walton RG, Thorton TL, Wahl GF. Serum methadone as an aid in managing methadone maintenance patients. Int J Addict 1978;13:689-94.